News
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena ...
Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis.
